No Data
JMP Securities Reiterates Market Outperform on BioAtla, Maintains $5 Price Target
BioAtla Analyst Ratings
BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity With Manageable Tolerability Among Heavily Pretreated Patients With Squamous Cell Carcinoma Of The Head And Neck At The 2024 ESMO Annual Meeting
JMP Securities Maintains BioAtla(BCAB.US) With Buy Rating, Maintains Target Price $5
JMP Securities analyst Reni Benjamin maintains $BioAtla(BCAB.US)$ with a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 33.9% and a
BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting
BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference